The FOA aims to facilitate the transition of SBIR and STTR Phase II projects to the commercialization stage by providing additional support for technical assistance not typically supported through Phase II or Phase IIB grants or contracts. This may include preparation of documents for a Food and Drug Administration (FDA) submission, development of an intellectual property strategy and/or planning for a clinical trial. Although a significant amount of the work in a CRP award may be subcontracted to other institutions, the SBC is expected to maintain oversight and management of the R&D throughout the award. NHLBI will support requests up to $50,000 for Phase II awardees. The Commercialization Readiness Pilot (CRP) Program will fund activities not traditionally allowed in SBIR/STTR grants.
Notice of NHLBI budget limitations: NOT-HL-15-283
For more information or questions, please read PAR-16-026 SBIR/STTR Commercialization Readiness Pilot (CRP) Program: Technical Assistance (SB1) or contact:
Jennifer C. Shieh, PhD
Small Business Coordinator & Program Director
The NHLBI SBIR/STTR Programs provide support for small businesses developing and commercializing novel technologies and products to promote the prevention, diagnosis, and treatment of heart, lung, blood, and sleep diseases and disorders. The NHLBI provides grant and contract funding for research and development of technologies related to the mission of NHLBI. For more information about the NHLBI SBIR/STTR Program, including funding opportunities, visit our web page.@NHLBI_SBIR | Sign up or adjust your subscription at the NHLBI-SBIR subscriber page